Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome

Dorte Glintborg, Rene Klinkby Støving, Claus Hagen, Anne Pernille Hermann, Jan Frystyk, Johannes D Veldhuis, Allan Flyvbjerg, Marianne Andersen

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Low GH levels, probably due to insulin resistance and increased abdominal fat mass, are well described in polycystic ovary syndrome (PCOS). GH acts as an important ovarian cogonadotropin, and GH disturbances may be an additional pathogenic factor in PCOS. Decreased abdominal fat mass and improved insulin sensitivity during pioglitazone treatment may affect GH secretion. Objective: The objective of the study was to investigate the effect of pioglitazone on GH levels in PCOS. Design: Thirty insulin-resistant PCOS patients were randomized to either 16 wk pioglitazone (30 mg/d) or placebo treatment. Before and after intervention, levels of fasting insulin, GH, total IGF-I, free IGF-I, IGF binding protein-1, IGF-II, free fatty acids, testosterone, and SHBG were measured. Patients underwent whole-body dual x-ray absorptiometry scans, pyridostigmine-GHRH tests, and 24-h 20-min integrated blood sampling for measurement of GH. Results: Peak GH and area under the curve for GH in pyridostigmine-GHRH tests and 24-h mean GH concentrations and pulsatile GH secretion significantly increased after pioglitazone treatment. No significant changes were observed in GH pulse frequency, pulse duration, approximate entropy levels, or basal GH release. Levels of IGF binding protein-1 significantly increased, whereas no significant differences were measured in total IGF-I and free IGF-I. Pioglitazone treatment significantly decreased fasting insulin and homeostasis model assessment levels. No significant changes were observed in Ferriman Gallwey score or androgen levels. Conclusion: Pioglitazone treatment significantly increased GHRH-stimulated GH levels and 24-h pulsatile GH secretion, probably directly or indirectly due to improved insulin sensitivity.

Original languageEnglish (US)
Pages (from-to)5605-5612
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume90
Issue number10
DOIs
StatePublished - Oct 2005

Fingerprint

pioglitazone
Polycystic Ovary Syndrome
Growth Hormone
Insulin
Insulin-Like Growth Factor I
Therapeutics
Pyridostigmine Bromide
Insulin-Like Growth Factor Binding Protein 1
Insulin Resistance
Abdominal Fat

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. / Glintborg, Dorte; Støving, Rene Klinkby; Hagen, Claus; Hermann, Anne Pernille; Frystyk, Jan; Veldhuis, Johannes D; Flyvbjerg, Allan; Andersen, Marianne.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 90, No. 10, 10.2005, p. 5605-5612.

Research output: Contribution to journalArticle

Glintborg, D, Støving, RK, Hagen, C, Hermann, AP, Frystyk, J, Veldhuis, JD, Flyvbjerg, A & Andersen, M 2005, 'Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome', Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 10, pp. 5605-5612. https://doi.org/10.1210/jc.2005-0615
Glintborg, Dorte ; Støving, Rene Klinkby ; Hagen, Claus ; Hermann, Anne Pernille ; Frystyk, Jan ; Veldhuis, Johannes D ; Flyvbjerg, Allan ; Andersen, Marianne. / Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. In: Journal of Clinical Endocrinology and Metabolism. 2005 ; Vol. 90, No. 10. pp. 5605-5612.
@article{87983d8f8e1a4240b46e0d8451adad6b,
title = "Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome",
abstract = "Background: Low GH levels, probably due to insulin resistance and increased abdominal fat mass, are well described in polycystic ovary syndrome (PCOS). GH acts as an important ovarian cogonadotropin, and GH disturbances may be an additional pathogenic factor in PCOS. Decreased abdominal fat mass and improved insulin sensitivity during pioglitazone treatment may affect GH secretion. Objective: The objective of the study was to investigate the effect of pioglitazone on GH levels in PCOS. Design: Thirty insulin-resistant PCOS patients were randomized to either 16 wk pioglitazone (30 mg/d) or placebo treatment. Before and after intervention, levels of fasting insulin, GH, total IGF-I, free IGF-I, IGF binding protein-1, IGF-II, free fatty acids, testosterone, and SHBG were measured. Patients underwent whole-body dual x-ray absorptiometry scans, pyridostigmine-GHRH tests, and 24-h 20-min integrated blood sampling for measurement of GH. Results: Peak GH and area under the curve for GH in pyridostigmine-GHRH tests and 24-h mean GH concentrations and pulsatile GH secretion significantly increased after pioglitazone treatment. No significant changes were observed in GH pulse frequency, pulse duration, approximate entropy levels, or basal GH release. Levels of IGF binding protein-1 significantly increased, whereas no significant differences were measured in total IGF-I and free IGF-I. Pioglitazone treatment significantly decreased fasting insulin and homeostasis model assessment levels. No significant changes were observed in Ferriman Gallwey score or androgen levels. Conclusion: Pioglitazone treatment significantly increased GHRH-stimulated GH levels and 24-h pulsatile GH secretion, probably directly or indirectly due to improved insulin sensitivity.",
author = "Dorte Glintborg and St{\o}ving, {Rene Klinkby} and Claus Hagen and Hermann, {Anne Pernille} and Jan Frystyk and Veldhuis, {Johannes D} and Allan Flyvbjerg and Marianne Andersen",
year = "2005",
month = "10",
doi = "10.1210/jc.2005-0615",
language = "English (US)",
volume = "90",
pages = "5605--5612",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome

AU - Glintborg, Dorte

AU - Støving, Rene Klinkby

AU - Hagen, Claus

AU - Hermann, Anne Pernille

AU - Frystyk, Jan

AU - Veldhuis, Johannes D

AU - Flyvbjerg, Allan

AU - Andersen, Marianne

PY - 2005/10

Y1 - 2005/10

N2 - Background: Low GH levels, probably due to insulin resistance and increased abdominal fat mass, are well described in polycystic ovary syndrome (PCOS). GH acts as an important ovarian cogonadotropin, and GH disturbances may be an additional pathogenic factor in PCOS. Decreased abdominal fat mass and improved insulin sensitivity during pioglitazone treatment may affect GH secretion. Objective: The objective of the study was to investigate the effect of pioglitazone on GH levels in PCOS. Design: Thirty insulin-resistant PCOS patients were randomized to either 16 wk pioglitazone (30 mg/d) or placebo treatment. Before and after intervention, levels of fasting insulin, GH, total IGF-I, free IGF-I, IGF binding protein-1, IGF-II, free fatty acids, testosterone, and SHBG were measured. Patients underwent whole-body dual x-ray absorptiometry scans, pyridostigmine-GHRH tests, and 24-h 20-min integrated blood sampling for measurement of GH. Results: Peak GH and area under the curve for GH in pyridostigmine-GHRH tests and 24-h mean GH concentrations and pulsatile GH secretion significantly increased after pioglitazone treatment. No significant changes were observed in GH pulse frequency, pulse duration, approximate entropy levels, or basal GH release. Levels of IGF binding protein-1 significantly increased, whereas no significant differences were measured in total IGF-I and free IGF-I. Pioglitazone treatment significantly decreased fasting insulin and homeostasis model assessment levels. No significant changes were observed in Ferriman Gallwey score or androgen levels. Conclusion: Pioglitazone treatment significantly increased GHRH-stimulated GH levels and 24-h pulsatile GH secretion, probably directly or indirectly due to improved insulin sensitivity.

AB - Background: Low GH levels, probably due to insulin resistance and increased abdominal fat mass, are well described in polycystic ovary syndrome (PCOS). GH acts as an important ovarian cogonadotropin, and GH disturbances may be an additional pathogenic factor in PCOS. Decreased abdominal fat mass and improved insulin sensitivity during pioglitazone treatment may affect GH secretion. Objective: The objective of the study was to investigate the effect of pioglitazone on GH levels in PCOS. Design: Thirty insulin-resistant PCOS patients were randomized to either 16 wk pioglitazone (30 mg/d) or placebo treatment. Before and after intervention, levels of fasting insulin, GH, total IGF-I, free IGF-I, IGF binding protein-1, IGF-II, free fatty acids, testosterone, and SHBG were measured. Patients underwent whole-body dual x-ray absorptiometry scans, pyridostigmine-GHRH tests, and 24-h 20-min integrated blood sampling for measurement of GH. Results: Peak GH and area under the curve for GH in pyridostigmine-GHRH tests and 24-h mean GH concentrations and pulsatile GH secretion significantly increased after pioglitazone treatment. No significant changes were observed in GH pulse frequency, pulse duration, approximate entropy levels, or basal GH release. Levels of IGF binding protein-1 significantly increased, whereas no significant differences were measured in total IGF-I and free IGF-I. Pioglitazone treatment significantly decreased fasting insulin and homeostasis model assessment levels. No significant changes were observed in Ferriman Gallwey score or androgen levels. Conclusion: Pioglitazone treatment significantly increased GHRH-stimulated GH levels and 24-h pulsatile GH secretion, probably directly or indirectly due to improved insulin sensitivity.

UR - http://www.scopus.com/inward/record.url?scp=26244435420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26244435420&partnerID=8YFLogxK

U2 - 10.1210/jc.2005-0615

DO - 10.1210/jc.2005-0615

M3 - Article

VL - 90

SP - 5605

EP - 5612

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 10

ER -